SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Microcap & Penny StocksTLT.v


Previous 10 Next 10 
To: 3bar who wrote (1400)10/19/2019 1:55:28 PM
From: 3bar
   of 1639
 
" Inviting Financial Advisors, Investment Advisors, Analysts and Institutional Portfolio Managers to attend Theralase Technologies Corporate Presentation & Lunch."


Could this be the sound of change ?

Share RecommendKeepReplyMark as Last Read


To: 3bar who wrote (1400)10/21/2019 6:09:19 AM
From: 3bar
   of 1639
 
Wrong ! We were notified in PR on Oct 7 2nd was treated with another news item . We will not be getting his 30 day on )ct. 25 th. . A specific date was not given in the PR but it would be a stretch .

So that makes one wonder why not wait for 2nds 30 day ? Or can they tell at 20 days as clearly as 30 ?

Share RecommendKeepReplyMark as Last Read


From: 3bar10/21/2019 9:27:13 AM
   of 1639
 
Same BOD , rog still in control from background who is going to commit ? Need more than 1 clean to move the needle even with nice venue ..

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: 3bar who wrote (1403)10/21/2019 9:59:17 AM
From: ogi
1 Recommendation   of 1639
 
tlc 2000 recalled by Health Canada it seems nothing changes with TLT ineptitude.

healthycanadians.gc.ca

Share RecommendKeepReplyMark as Last Read


From: 3bar10/24/2019 7:38:11 PM
   of 1639
 
The science team at TLT . stockhouse.com

Nice job by roger getting them all together .

Share RecommendKeepReplyMark as Last Read


From: 3bar10/26/2019 10:33:59 AM
1 Recommendation   of 1639
 
Like the way these lads see it . stockhouse.com

Share RecommendKeepReplyMark as Last Read


From: 3bar10/29/2019 7:50:21 AM
   of 1639
 
A reminder if you do your own investing you will do much better with a group of like minded who work in a way to complement each other . Having those clearly better informed then you in the group is a money saving necessity .

Do not try do do it alone .

Share RecommendKeepReplyMark as Last Read


From: Liberator11/1/2019 9:30:38 AM
   of 1639
 
I still have less than a full position in this...thank goodness.
Is Kipton's departure a positive or negative?

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="TORONTO, ON / ACCESSWIRE / October 31, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today the departure of its Chief Executive Officer - Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer - Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth." style="margin: 0px 0px 1em; font-family: Georgia, "Times New Roman", serif; font-size: 18px; background-color: rgb(255, 255, 255);">TORONTO, ON / ACCESSWIRE / October 31, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today the departure of its Chief Executive Officer - Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer - Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth.

"We thank Kipton for his contributions to the Company over the last 8 months and we wish him well," said Theralase Technologies Chairman of the Board of Directors, Guy Anderson. "We are also excited with the prospects of the TLD-1433 Anti-Cancer Technology ("ACT") platform as it has the potential to be a viable treatment solution for patients who present with Carcinoma In-Situ ("CIS") Non-Muscle Invasive Bladder Cancer ("NMIBC") and who are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive."

The Company has commenced a Phase II NMIBC clinical study to enroll and treat patients who present with CIS and who are considered BCG-Unresponsive or are intolerant to BCG Therapy ("Study II"). The Company has three sites open for patient enrollment and treatment; specifically, University Health Network ("UHN"), McGill University Health Centre ("MUHC") and London Health Sciences Centre ("LHSC"). All sites are actively recruiting and screening new patients for enrollment in Study II. In addition, the Company has approximately six clinical study sites located in Canada and the US that are at various stages of the on-boarding process. The Company is specifically targeting strategic clinical sites throughout Canada and the US (subject to FDA Investigational New Drug ("IND") approval) that serve large populations or have the demographics to support patient enrollment and treatment. The Company anticipates that patient enrollment and treatment will escalate rapidly as it launches additional clinical study sites.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="About Theralase® Technologies Inc." style="margin: 0px 0px 1em; font-family: Georgia, "Times New Roman", serif; font-size: 18px; background-color: rgb(255, 255, 255);">About Theralase® Technologies Inc.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Liberator who wrote (1408)11/1/2019 12:02:36 PM
From: ogi
1 Recommendation   of 1639
 
Really hard to say what is going on. Given that TLT's 2000 system has been recalled by Health Canada for numerous deficiencies iit would be hard to blame that all on his first year. I assume he inherited many problems from RDW who, as part of his censure by the OSC, was disciplined for claiming full Government compliance in the laser division which was not true. So, one has to assume he was not comfortable that the opportunity he belived was ahead of him on hiring was not there in reality. If you have Linkedin keep an eye on him. Would love to do an exit survey with him:)

If you like the prospects of TLT but wish to minimize exposure there are the warrants TLT.wt, they have a 5 year term and give the right to purchase at .35. However I think the stock is the better deal at current prices

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


From: 3bar11/1/2019 12:11:02 PM
   of 1639
 
My take is sentiment has changed . Bollies are tight waiting for the news to break it out and up .

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10